Citadel Advisors
AMPE

Citadel Advisors’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

Citadel Advisors’s Portfolio AMPE Stock Details AMPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-389
Closed -$1.81K – 15782
2023
Q1 		$1.81K Sell
389
-224
-37% -$1.26K ﹤0.01% 14243
2022
Q4 		$2.76K Sell
613
-9
-1% -$58 ﹤0.01% 14286
2022
Q3 		$11K Sell
622
-169
-21% -$5.92K ﹤0.01% 12269
2022
Q2 		$40K Buy
791
+96
+14% +$7.14K ﹤0.01% 12070
2022
Q1 		$98K Sell
695
-189
-21% -$27.6K ﹤0.01% 12308
2021
Q4 		$151K Sell
884
-237
-21% -$88.4K ﹤0.01% 12251
2021
Q3 		$558K Sell
1,121
-71
-6% -$32.9K ﹤0.01% 9603
2021
Q2 		$597K Buy
1,192
+175
+17% +$94K ﹤0.01% 9635
2021
Q1 		$515K Buy
1,017
+365
+56% +$188K ﹤0.01% 9610
2020
Q4 		$311K Buy
652
+344
+112% +$113K ﹤0.01% 9015
2020
Q3 		$88K Buy
308
+146
+90% +$36.2K ﹤0.01% 9351
2020
Q2 		$31K Buy
162
+5
+3% +$832 ﹤0.01% 9456
2020
Q1 		$20K Sell
157
-214
-58% -$38.7K ﹤0.01% 9307
2019
Q4 		$65K Buy
371
+77
+26% +$9.95K ﹤0.01% 8688
2019
Q3 		$44K Sell
294
-93
-24% -$12.4K ﹤0.01% 8741
2019
Q2 		$45K Sell
387
-91
-19% -$14.4K ﹤0.01% 8758
2019
Q1 		$81K Sell
478
-234
-33% -$40.1K ﹤0.01% 8631
2018
Q4 		$84K Buy
712
+218
+44% +$33.5K ﹤0.01% 8321
2018
Q3 		$75K Buy
494
+365
+283% +$153K ﹤0.01% 8683
2018
Q2 		$85K Sell
129
-397
-75% -$297K ﹤0.01% 8306
2018
Q1 		$537K Buy
526
+140
+36% +$117K ﹤0.01% 5767
2017
Q4 		$471K Buy
386
+219
+131% +$103K ﹤0.01% 5746
2017
Q3 		$31K Buy
167
+67
+67% +$10.6K ﹤0.01% 7284
2017
Q2 		$16K Buy
100
+16
+19% +$3.24K ﹤0.01% 7337
2017
Q1 		$20K Sell
84
-22
-21% -$5.91K ﹤0.01% 7248
2016
Q4 		$29K Buy
106
+34
+47% +$8.1K ﹤0.01% 7000
2016
Q3 		$16K Sell
72
-120
-63% -$33.6K ﹤0.01% 7106
2016
Q2 		$74K Buy
+192
New +$210K ﹤0.01% 6310
2016
Q1 		– Sell
-313
Closed -$329K – 8338
2015
Q4 		$329K Buy
313
+82
+35% +$81.1K ﹤0.01% 5092
2015
Q3 		$201K Sell
231
-76
-25% -$63.6K ﹤0.01% 6150
2015
Q2 		$219K Sell
307
-66
-18% -$70.3K ﹤0.01% 6199
2015
Q1 		$842K Buy
373
+264
+242% +$450K ﹤0.01% 4163
2014
Q4 		$113K Sell
109
-12
-10% -$12.8K ﹤0.01% 6545
2014
Q3 		$128K Sell
121
-68
-36% -$114K ﹤0.01% 6181
2014
Q2 		$473K Buy
189
+73
+63% +$149K ﹤0.01% 4475
2014
Q1 		$220K Sell
116
-20
-15% -$47.3K ﹤0.01% 5418
2013
Q4 		$292K Buy
136
+93
+216% +$220K ﹤0.01% 4629
2013
Q3 		$98K Buy
+43
New +$83.2K ﹤0.01% 5365

Other funds holding AMPE

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Citadel Advisors's AMPE Position: Q2 2023 in Review

Citadel Advisors sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q2 2023, closing a stake of 382 shares — an estimated $1.78K sold.

Citadel Advisors first reported a position in AMPE in Q3 2013 and held it in 34 quarters. The position peaked at $824K in Q2 2014. 34 funds tracked by Wall St. Rank hold AMPE as of Q2 2023.

  • Citadel Advisors reported no remaining Ampio Pharmaceuticals Inc. position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 382 Ampio Pharmaceuticals Inc. shares in Q2 2023, an estimated $1.78K.
  • Citadel Advisors first reported a position in Ampio Pharmaceuticals Inc. in Q3 2013 and held it in 34 quarters.
  • Citadel Advisors's Ampio Pharmaceuticals Inc. position peaked at $824K in Q2 2014.
  • 34 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.